{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:31:10Z","timestamp":1791307870362,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,13]],"date-time":"2008-12-13T00:00:00Z","timestamp":1229126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11095-008-9782-1","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T15:50:07Z","timestamp":1229097007000},"page":"836-845","source":"Crossref","is-referenced-by-count":77,"title":["Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231"],"prefix":"10.1007","volume":"26","author":[{"given":"Sonia","family":"Aroui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Appaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ronjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderraouf","family":"Kenani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Pirollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"De Waard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,13]]},"reference":[{"key":"9782_CR1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/BST0350767","volume":"35","author":"J. Howl","year":"2007","unstructured":"J. Howl, I. D. Nicholl, and S. Jones. The many futures for cell-penetrating peptides: how soon is now. Biochem. Soc. Trans. 35:767\u2013769 (2007).","journal-title":"Biochem. Soc. Trans."},{"issue":"Pt 4","key":"9782_CR2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1242\/jcs.102.4.717","volume":"102","author":"F. Perez","year":"1992","unstructured":"F. Perez, A. Joliot, E. Bloch-Gallego, A. Zahraoui, A. Triller, and A. Prochiantz. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J. Cell Sci. 102(Pt 4):717\u2013722 (1992).","journal-title":"J. Cell Sci."},{"key":"9782_CR3","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.88.5.1864","volume":"88","author":"A. Joliot","year":"1991","unstructured":"A. Joliot, C. Pernelle, H. Deagostini-Bazin, and A. Prochiantz. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Nat. Acad. Sci. U S A. 88:1864\u20131868 (1991).","journal-title":"Proc. Nat. Acad. Sci. U S A"},{"key":"9782_CR4","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","volume":"269","author":"D. Derossi","year":"1994","unstructured":"D. Derossi, A. H. Joliot, G. Chassaing, and A. Prochiantz. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:10444\u201310450 (1994).","journal-title":"J. Biol. Chem."},{"key":"9782_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0962-8924(98)80017-2","volume":"8","author":"D. Derossi","year":"1998","unstructured":"D. Derossi, G. Chassaing, and A. Prochiantz. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8:84\u201387 (1998).","journal-title":"Trends Cell Biol."},{"key":"9782_CR6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coph.2006.04.004","volume":"6","author":"M. Mae","year":"2006","unstructured":"M. Mae, and U. Langel. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 6:509\u2013514 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"9782_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.addr.2004.10.010","volume":"57","author":"M. Zorko","year":"2005","unstructured":"M. Zorko, and U. Langel. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57:529\u2013545 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9782_CR8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1359-6446(04)03279-9","volume":"9","author":"J. Temsamani","year":"2004","unstructured":"J. Temsamani, and P. Vidal. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today. 9:1012\u20131019 (2004).","journal-title":"Drug Discov. Today"},{"key":"9782_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(00)01239-4","volume":"469","author":"Z. Fajloun","year":"2000","unstructured":"Z. Fajloun, R. Kharrat, L. Chen, C. Lecomte, E. Di Luccio, D. Bichet, M. El Ayeb, H. Rochat, P.D. Allen, I.N. Pessah, M. De Waard, and J.M. Sabatier. Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca(2+) release channel\/ryanodine receptors. FEBS Lett. 469:179\u2013185 (2000).","journal-title":"FEBS Lett."},{"key":"9782_CR10","doi-asserted-by":"crossref","first-page":"37822","DOI":"10.1074\/jbc.M305798200","volume":"278","author":"E. Esteve","year":"2003","unstructured":"E. Esteve, S. Smida-Rezgui, S. Sarkozi, C. Szegedi, I. Regaya, L. Chen, X. Altafaj, H. Rochat, P. Allen, I. N. Pessah, I. Marty, J. M. Sabatier, I. Jona, M. De Waard, and M. Ronjat. Critical amino acid residues determine the binding affinity and the Ca2+ release efficacy of maurocalcine in skeletal muscle cells. J. Biol. Chem. 278:37822\u201337831 (2003).","journal-title":"J. Biol. Chem."},{"key":"9782_CR11","doi-asserted-by":"crossref","first-page":"12833","DOI":"10.1074\/jbc.M412521200","volume":"280","author":"E. Esteve","year":"2005","unstructured":"E. Esteve, K. Mabrouk, A. Dupuis, S. Smida-Rezgui, X. Altafaj, D. Grunwald, J. C. Platel, N. Andreotti, I. Marty, J. M. Sabatier, M. Ronjat, and M. De Waard. Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. J. Biol. Chem. 280:12833\u201312839 (2005).","journal-title":"J. Biol. Chem."},{"key":"9782_CR12","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.bbamem.2007.06.030","volume":"1768","author":"K. Mabrouk","year":"2007","unstructured":"K. Mabrouk, N. Ram, S. Boisseau, F. Strappazzon, A. Rehaim, R. Sadoul, H. Darbon, M. Ronjat, and M. De Waard. Critical amino acid residues of maurocalcine involved in pharmacology, lipid interaction and cell penetration. Biochim. Biophys. Acta. 1768:2528\u20132540 (2007).","journal-title":"Biochim. Biophys. Acta."},{"key":"9782_CR13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/1097-0134(20000815)40:3<436::AID-PROT90>3.0.CO;2-9","volume":"40","author":"A. Mosbah","year":"2000","unstructured":"A. Mosbah, R. Kharrat, Z. Fajloun, J. G. Renisio, E. Blanc, J. M. Sabatier, M. El Ayeb, and H. Darbon. A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Proteins. 40:436\u2013442 (2000).","journal-title":"Proteins"},{"key":"9782_CR14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0005-2736(01)00447-3","volume":"1559","author":"G. Drinand","year":"2002","unstructured":"G. Drinand, and J. Temsamani. Translocation of protegrin I through phospholipid membranes: role of peptide folding. Biochim. Biophys. Acta. 1559:160\u2013170 (2002).","journal-title":"Biochim. Biophys. Acta."},{"key":"9782_CR15","doi-asserted-by":"crossref","unstructured":"N. Ram, N. Weiss, I. Texier-Nogues, S. Aroui, N. Andreotti, F. Pirollet, M. Ronjat, J.M. Sabatier, H. Darbon, V. Jacquemond, and M. De Waard. Design of a disulfide-less, pharmacologically-inert and chemically-competent analog of maurocalcine for the efficient transport of impermeant compounds into cells. J. Biol. Chem. 283:27048\u201327056 (2008).","DOI":"10.1074\/jbc.M804727200"},{"key":"9782_CR16","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2004.07.190","volume":"22","author":"G. Bonadonna","year":"2004","unstructured":"G. Bonadonna, M. Zambetti, A. Moliterni, L. Gianni, and P. Valagussa. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J. Clin. Oncol. 22:1614\u20131620 (2004).","journal-title":"J. Clin. Oncol."},{"key":"9782_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1634\/theoncologist.11-2-111","volume":"11","author":"M. Colozza","year":"2006","unstructured":"M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 11:111\u2013125 (2006).","journal-title":"Oncologist"},{"key":"9782_CR18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/jpet.106.101154","volume":"317","author":"H. L. Wong","year":"2006","unstructured":"H. L. Wong, R. Bendayan, A. M. Rauth, H. Y. Xue, K. Babakhanian, and X. Y. Wu. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer\u2013lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 317:1372\u20131381 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9782_CR19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G. Szakacs","year":"2006","unstructured":"G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5:219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9782_CR20","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1535-7163.MCT-06-0190","volume":"5","author":"L. Smith","year":"2006","unstructured":"L. Smith, M. B. Watson, S. L. O\u2019Kane, P. J. Drew, M. J. Lind, and L. Cawkwell. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 5:2115\u20132120 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"9782_CR21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1124\/mol.105.016519","volume":"68","author":"J. C. Mallory","year":"2005","unstructured":"J. C. Mallory, G. Crudden, A. Oliva, C. Saunders, A. Stromberg, and R. J. Craven. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol. Pharmacol. 68:1747\u20131756 (2005).","journal-title":"Mol. Pharmacol."},{"key":"9782_CR22","first-page":"1425","volume":"13","author":"M. Torre de la","year":"1993","unstructured":"M. de la Torre, X. Y. Hao, R. Larsson, P. Nygren, T. Tsuruo, B. Mannervik, and J. Bergh. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res. 13:1425\u20131430 (1993).","journal-title":"Anticancer Res."},{"key":"9782_CR23","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.1158\/0008-5472.CAN-06-1521","volume":"66","author":"D. S. Kim","year":"2006","unstructured":"D. S. Kim, S. S. Park, B. H. Nam, I. H. Kim, and S. Y. Kim. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 66:10936\u201310943 (2006).","journal-title":"Cancer Res."},{"key":"9782_CR24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.yexcr.2006.12.004","volume":"313","author":"Y. Fang","year":"2007","unstructured":"Y. Fang, R. Sullivan, and C. H. Graham. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res. 313:867\u2013877 (2007).","journal-title":"Exp Cell Res."},{"key":"9782_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2004.11.017","volume":"103","author":"M. Hruby","year":"2005","unstructured":"M. Hruby, C. Konak, and K. Ulbrich. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J. Control Release. 103:137\u2013148 (2005).","journal-title":"J. Control Release."},{"key":"9782_CR26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ejpb.2007.02.016","volume":"66","author":"F. Tewes","year":"2007","unstructured":"F. Tewes, E. Munnier, B. Antoon, L. Ngaboni Okassa, S. Cohen-Jonathan, H. Marchais, L. Douziech-Eyrolles, M. Souce, P. Dubois, and I. Chourpa. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur. J. Pharm. Biopharm. 66:488\u2013492 (2007).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"9782_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1054\/drup.2000.0138","volume":"3","author":"U. Massing","year":"2000","unstructured":"U. Massing, and S. Fuxius. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist. Updat. 3:171\u2013177 (2000).","journal-title":"Drug Resist. Updat."},{"key":"9782_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2004.09.005","volume":"23","author":"G. Stefano Di","year":"2004","unstructured":"G. Di Stefano, M. Lanza, F. Kratz, L. Merina, and L. Fiume. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur. J. Pharm. Sci. 23:393\u2013397 (2004).","journal-title":"Eur. J. Pharm. Sci."},{"key":"9782_CR29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.dld.2006.02.010","volume":"38","author":"G. Stefano Di","year":"2006","unstructured":"G. Di Stefano, L. Fiume, M. Domenicali, C. Busi, P. Chieco, F. Kratz, M. Lanza, A. Mattioli, M. Pariali, and M. Bernardi. Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. Dig. Liver Dis. 38:404\u2013408 (2006).","journal-title":"Dig. Liver Dis."},{"key":"9782_CR30","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1016\/j.bmcl.2005.07.087","volume":"15","author":"J. F. Liang","year":"2005","unstructured":"J. F. Liang, and V. C. Yang. Synthesis of doxorubicin\u2013peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg. Med. Chem. Lett. 15:5071\u20135075 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"9782_CR31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-4781(98)00134-1","volume":"1400","author":"K. R. Hande","year":"1998","unstructured":"K. R. Hande. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta. 1400:173\u2013184 (1998).","journal-title":"Biochim. Biophys. Acta."},{"key":"9782_CR32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.107.127704","volume":"324","author":"F. Shen","year":"2008","unstructured":"F. Shen, S. Chu, A. K. Bence, B. Bailey, X. Xue, P. A. Erickson, M. H. Montrose, W. T. Beck, and L. C. Erickson. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 324:95\u2013102 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9782_CR33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","volume":"6","author":"S. Modok","year":"2006","unstructured":"S. Modok, H. R. Mellor, and R. Callaghan. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 6:350\u2013354 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"9782_CR34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"F. J. Sharom","year":"2008","unstructured":"F. J. Sharom. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 9:105\u2013127 (2008).","journal-title":"Pharmacogenomics"},{"key":"9782_CR35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0306-3623(95)02013-6","volume":"27","author":"D. Nielsen","year":"1996","unstructured":"D. Nielsen, C. Maare, and T. Skovsgaard. Cellular resistance to anthracyclines. Gen. Pharmacol. 27:251\u2013255 (1996).","journal-title":"Gen. Pharmacol."},{"key":"9782_CR36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/bjc.1993.452","volume":"68","author":"G. J. Schuurhuis","year":"1993","unstructured":"G. J. Schuurhuis, T. H. van Heijningen, A. Cervantes, H. M. Pinedo, J. H. de Lange, H. G. Keizer, H. J. Broxterman, J. P. Baak, and J. Lankelma. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br. J. Cancer. 68:898\u2013908 (1993).","journal-title":"Br. J. Cancer"},{"key":"9782_CR37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1054\/drup.1999.0083","volume":"2","author":"L.I. McLellan","year":"1999","unstructured":"L.I. McLellan, and C. R. Wolf. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat. 2:153\u2013164 (1999).","journal-title":"Drug Resist Updat."},{"key":"9782_CR38","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1021\/bi700416h","volume":"46","author":"A. Ziegler","year":"2007","unstructured":"A. Ziegler, and J. Seelig. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA. Biochemistry. 46:8138\u20138145 (2007).","journal-title":"Biochemistry"},{"key":"9782_CR39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-2952(01)00928-5","volume":"63","author":"Y. Hensbergen van","year":"2002","unstructured":"Y. van Hensbergen, H. J. Broxterman, Y. W. Elderkamp, J. Lankelma, J. C. Beers, M. Heijn, E. Boven, K. Hoekman, and H. M. Pinedo. A doxorubicin\u2013CNGRC\u2013peptide conjugate with prodrug properties. Biochem. Pharmacol. 63:897\u2013908 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"9782_CR40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bbamem.2006.02.007","volume":"1758","author":"S. Boisseau","year":"2006","unstructured":"S. Boisseau, K. Mabrouk, N. Ram, N. Garmy, V. Collin, A. Tadmouri, M. Mikati, J.M. Sabatier, M. Ronjat, J. Fantini, and M. De Waard. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim. Biophys. Acta. 1758:308\u2013319 (2006).","journal-title":"Biochim. Biophys. Acta."},{"key":"9782_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI27527","volume":"117","author":"G. A. Gusarova","year":"2007","unstructured":"G. A. Gusarova, I. C. Wang, M. L. Major, V. V. Kalinichenko, T. Ackerson, V. Petrovic, and R. H. Costa. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 117:99\u2013111 (2007).","journal-title":"J. Clin. Invest."},{"key":"9782_CR42","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1021\/bi060264j","volume":"45","author":"Y. Kim","year":"2006","unstructured":"Y. Kim, A. M. Lillo, S. C. Steiniger, Y. Liu, C. Ballatore, A. Anichini, R. Mortarini, G. F. Kaufmann, B. Zhou, B. Felding-Habermann, and K. D. Janda. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry. 45:9434\u20139444 (2006).","journal-title":"Biochemistry"},{"key":"9782_CR43","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/0008-5472.CAN-04-2086","volume":"64","author":"S. E. Perea","year":"2004","unstructured":"S. E. Perea, O. Reyes, Y. Puchades, O. Mendoza, N. S. Vispo, I. Torrens, A. Santos, R. Silva, B. Acevedo, E. Lopez, V. Falcon, and D. F. Alonso. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64:7127\u20137129 (2004).","journal-title":"Cancer Res."},{"key":"9782_CR44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1254\/jphs.FPZ070263","volume":"106","author":"M. Hirose","year":"2008","unstructured":"M. Hirose, M. Takatori, Y. Kuroda, M. Abe, E. Murata, T. Isada, K. Ueda, K. Shigemi, M. Shibazaki, F. Shimizu, M. Hirata, K. Fukazawa, M. Sakaguchi, K. Kageyama, and Y. Tanaka. Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells. J. Pharmacol. Sci. 106:107\u2013113 (2008).","journal-title":"J. Pharmacol. Sci."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-008-9782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-008-9782-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-008-9782-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T17:29:40Z","timestamp":1632763780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-008-9782-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,13]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["9782"],"URL":"https:\/\/doi.org\/10.1007\/s11095-008-9782-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,13]]}}}